Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
30 shown of 2,504 total abstracts
  1. Abstract LBA4000LBA2026-09-04 · 21:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-707 study)
    P. Schmid, N. Rizvi, E. Winer · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract LBA4001LBA2026-09-04 · 21:30 CT · Hall B1
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-321
    S. Peters, L. Paz-Ares, M. Krop · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract LBA4002LBA2026-09-05 · 20:30 CT · S406
    MONALEESA-921: Kisqali (ribociclib) 2L in HR+ breast cancer
    C. Saura, T. Mok, R. Herbst, et al. · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract LBA4003LBA2026-09-03 · 21:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-214
    J. Cortes, L. Paz-Ares, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-09-04 · 18:45 CT · S100A
    MONALEESA-985: Kisqali (ribociclib) 1L in HR+ breast cancer
    S. Peters, M. Reck, M.C. Garassino · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract LBA4005LBA2026-09-03 · 18:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-890
    R. Herbst, C. Robert, S. Modi, et al. · Karolinska Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-09-01 · 14:15 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    L. Paz-Ares, M.C. Garassino, S. Peters · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract LBA4007LBA2026-09-03 · 18:15 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    S. Antonia, S. Tolaney, S. Modi, et al. · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract LBA4008LBA2026-09-01 · 19:45 CT · E450
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    N. Rizvi, J. Brahmer, R. Herbst, et al. · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-09-01 · 15:30 CT · Hall B1
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-802
    N. Rizvi, T. Mok, S. Tolaney, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract LBA4010LBA2026-09-02 · 19:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-172
    H. Rugo, S. Peters, F. Andre · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract LBA4011LBA2026-09-04 · 13:15 CT · S406
    Long-term follow-up of Keytruda 3L+ for TNBC: KEYNOTE-94
    A. Spira, P. Schmid, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract LBA4012LBA2026-09-01 · 16:00 CT · Hall B1
    MONALEESA-576: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    T. Mok, M. Krop, S. Antonia, et al. · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract LBA4013LBA2026-09-04 · 19:45 CT · Hall B1
    PALOMA-947: Ibrance (palbociclib) maintenance in HR+ breast cancer
    E. Winer, H. Borghaei · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract LBA4014LBA2026-09-04 · 13:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with TNBC
    J. Cortes, P. Schmid, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract LBA4015LBA2026-09-02 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-668 study)
    C. Robert, H. Borghaei · Vall d'Hebron Institute of Oncology
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract LBA4016LBA2026-09-02 · 16:15 CT · S100A
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    H. Borghaei, E. Winer, T. Mok, et al. · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract LBA4017LBA2026-09-05 · 19:15 CT · E450
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-59
    H. Borghaei, M.C. Garassino, F. Andre, et al. · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract LBA4018LBA2026-09-03 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-259 study)
    L. Paz-Ares, S. Antonia, M. Reck, et al. · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract LBA4019LBA2026-09-02 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-985 study)
    C. Robert, P. Schmid, A. Spira · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract LBA4020LBA2026-09-04 · 16:15 CT · S406
    OlympiA-146: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    E. Winer, H. Rugo, C. Robert, et al. · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract LBA4021LBA2026-09-04 · 18:30 CT · E450
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-311
    G. Curigliano, J. Cortes, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract LBA4022LBA2026-09-02 · 21:45 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    R. Herbst, S. Peters, C. Saura, et al. · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract LBA4023LBA2026-09-02 · 20:45 CT · E450
    Quality of life outcomes with Tecentriq in patients with TNBC
    C. Saura, S. Peters, M. Krop · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract LBA4024LBA2026-09-01 · 19:30 CT · S406
    Quality of life outcomes with Trodelvy in patients with TNBC
    P. Schmid, S. Tolaney · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract LBA4025LBA2026-09-05 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-635 study)
    S. Modi, M. Krop, P. Schmid · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract LBA4026LBA2026-09-02 · 14:45 CT · E450
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    J. Brahmer, E. Winer, A. Spira, et al. · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract LBA4027LBA2026-09-02 · 14:45 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    M.C. Garassino, C. Saura, S. Antonia · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract LBA4028LBA2026-09-01 · 16:00 CT · E450
    PALOMA-923: Ibrance (palbociclib) maintenance in HR+ breast cancer
    R. Herbst, A. Spira, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract LBA4029LBA2026-09-04 · 13:15 CT · S406
    MONALEESA-583: Kisqali (ribociclib) 1L in HR+ breast cancer
    C. Saura, G. Curigliano, H. Borghaei, et al. · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.